VANCALLO - Prevention of C. difficile infections by oral vancomycin in patients treated for allogeneic hematopoietic stem cell transplantation, a randomized double-blind placebo-controlled trial
People who have a stem cell transplant from a donor need intensive treatments that lower their immune system. This puts them at high risk of developing Clostridium difficile (or C. diff), a bacterial gut bug that causes severe, watery diarrhoea and bowel pain. The VANCALLO trial looks at whether taking an antibiotic called vancomycin as a liquid by mouth can stop C. diff before it starts. Adult patients staying in hospital for a transplant are randomly placed into one of two groups. One group receives oral vancomycin, and the other receives an inactive saltwater liquid (a placebo). Neither the patient nor their doctors will know which treatment is given. Researchers will track participants for up to 12 weeks to see whether vancomycin lowers infection rates, without causing unwanted side effects or encouraging antibiotic resistance.
At a glance
What is this study about?
When you receive a stem cell transplant from a donor (an allogeneic transplant), your immune system is temporarily suppressed to help the new cells settle in. During your hospital stay, you also need strong antibiotics and other treatments to protect your body. While vital, these treatments can clear away the friendly bacteria that live in your gut.
Without these friendly bacteria to keep things in balance, harmful bacteria can quickly multiply. The most common threat is Clostridium difficile, commonly known as C. diff. A C. diff infection causes severe, watery diarrhoea, fever, and painful gut inflammation. For someone recovering from a stem cell transplant, a C. diff infection can cause major setbacks, lengthen hospital stays, and lead to dangerous complications.
Vancomycin is a trusted antibiotic commonly used to treat C. diff once an infection has already taken hold. This clinical trial wants to find out if giving a low dose of vancomycin liquid as a preventive shield can stop C. diff from ever developing in the first place.
By comparing vancomycin directly against a dummy treatment (placebo), researchers hope to learn whether this preventive approach is safe, effective, and worth making a standard part of hospital care for future stem cell transplant patients.
Key takeaways
- The trial tests whether oral vancomycin can prevent C. diff gut infections in donor stem cell transplant patients.
- Open to hospitalized adults aged 18 and over who are having an allogeneic stem cell transplant.
- Participants take either vancomycin liquid or a dummy liquid (placebo) for up to five weeks.
- Your health and bowel habits will be monitored during your stay and followed up for 12 weeks.
- Participation is entirely voluntary and will not impact your regular hospital care.
Who may be eligible?
This trial is open to adults aged 18 and older who are admitted to hospital to undergo an allogeneic stem cell transplant (a transplant using stem cells from a healthy donor). Both men and women can join.
You might not be suitable for the study if you already have an active C. diff infection, if you have a known allergy to vancomycin, or if your medical team decides that taking part could interfere with your other essential transplant medicines. Your hospital care team will check your full medical history before you enrol.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I am scheduled to stay in hospital for an allogeneic stem cell transplant (using donor cells).
- I do not have a known allergy or sensitivity to vancomycin.
- I do not currently have an active C. diff gut infection.
What does participation involve?
If you take part, you will be randomly assigned by a computer to receive either oral vancomycin liquid or a dummy liquid (placebo). You take this liquid by mouth every day while you are in hospital, for up to five weeks.
During your stay, the nursing and medical team will closely monitor your tummy symptoms. If you develop diarrhoea, a stool sample will be tested in the laboratory. Researchers will also take gentle swab samples (including a rectal swab) at the start and end of treatment to check the balance of bacteria in your bowel. After your treatment ends, your health will be monitored until week 12 to check for any delayed gut infections or side effects.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is an allogeneic stem cell transplant?
It is a specialised medical treatment where you receive healthy, blood-forming stem cells donated by another person to replace your own damaged or diseased cells.
What is a placebo and why is it used?
A placebo is an inactive 'dummy' liquid that looks and tastes like the real medicine. It allows doctors to fairly measure whether vancomycin truly prevents infections compared with standard care alone.
Will I or my doctor know which treatment I receive?
No. This is a 'double-blind' trial, so neither you nor your doctors will know whether you are taking vancomycin or the placebo. In a medical emergency, your team can find out immediately.
What happens if I get diarrhoea during the trial?
Tell your care team straight away. They will test a stool sample for C. diff. If you have an infection, you will be given full, prompt medical treatment regardless of which study group you are in.
Will taking part alter my normal transplant care?
No. You will continue to receive all of your planned transplant conditioning, donor cells, and standard supportive medicines exactly as normal.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.